# Peppermint Functional Dyspepsia Meta-analysis: What the Evidence Says
Canonical: https://www.migaku.app/guides/peppermint-functional-dyspepsia-meta-analysis-evidence-review
Category: evidence-review
Summary: Peppermint Functional Dyspepsia Meta-analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pa
Last reviewed: 2026-07-06
Reviewed by: Migaku Evidence Review
# Peppermint Functional Dyspepsia Meta-analysis: What the Evidence Says

## Quick Answer

Peppermint Functional Dyspepsia Meta-analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are guideline, so conclusions should be framed as evidence-aware guidance rather than medical advice.

## Key Takeaways

- This page is generated only from sources stored in the Migaku evidence knowledge base.
- Current evidence mix: 1 guideline, 1 narrative review.
- Claims should be interpreted with the source type, study design, population, and publication date in mind.
- This article is educational and does not replace care from a qualified clinician.

## Evidence Map

| Source | Evidence type | Level | Date | Identifier |
| --- | --- | ---: | --- | --- |
| S1 Guideline of the German Society for Neurogastroenterology and Motility (DGNM) on Functional Dyspepsia (FD), a Disorder of Gut–Brain Interaction (DGBI) [English Language Edition] | guideline | 2 | 2026-05-05 | 10.1155/grp/2610765 |
| Diagnosis and management of irritable bowel syndrome | narrative review | 3 | 2026-06-02 | 10.18773/austprescr.2026.018 |

## What The Sources Report

- Of the more than 70,000 people included in the survey, 40% showed clear evidence of FGID, according to the Rome IV criteria. [Storr M. (2026); evidence level 2]
- Low-grade intestinal inflammation with increased mast cells has been observed in some IBS cohorts., A dysbiotic or less diverse gut microbiome may be present in IBS, and small intestinal bacterial overgrowth occurs in a subset of patients; however, routine testing is not of clinical value. [Morrison Savannah (2026); evidence level 3]
- Many studies support a strong psychosocial foundation for IBS, particularly seen in patients who report higher levels of daily stress and those with increased anxiety, depression, and somatic symptoms.There is often a genetic predisposition for IBS. [Morrison Savannah (2026); evidence level 3]

## How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

## Practical Interpretation

For peppermint functional dyspepsia meta-analysis, the current source set is useful for orientation, but it is not yet broad enough for strong claims. Use cautious language and keep conclusions close to the cited sources.

## Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

## References

- Storr M. (2026). S1 Guideline of the German Society for Neurogastroenterology and Motility (DGNM) on Functional Dyspepsia (FD), a Disorder of Gut–Brain Interaction (DGBI) [English Language Edition]. DOI: 10.1155/grp/2610765. PMCID: PMC13140302. PMID: 42095009. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13140302/
- Morrison Savannah (2026). Diagnosis and management of irritable bowel syndrome. DOI: 10.18773/austprescr.2026.018. PMCID: PMC13268845. PMID: 42312308. License: https://creativecommons.org/licenses/by-nc-nd/4.0/. https://pmc.ncbi.nlm.nih.gov/articles/PMC13268845/

## Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.